• Home
  • About
  • Contact
  • Steve Walker
  • Subscriptions
    • Sample MondayMorning Newsletter January 11, 2016
Monday Morning
Skip to content
  • Home
  • About
  • Contact
  • Steve Walker
  • Subscriptions
    • Sample MondayMorning Newsletter January 11, 2016

Tag Archives: Pharmacy Times

FTC opens antitrust investigation of Mylan’s EpiPen dominance; isn’t it high time we live up to Churchill’s rejoinder?

Steve Walker    February 8, 2017 September 6, 2017    No Comments on FTC opens antitrust investigation of Mylan’s EpiPen dominance; isn’t it high time we live up to Churchill’s rejoinder?

The News: Mylan on Monday (January 30, 2017) acknowledged that the US Federal Trade Commission asked the company “months ago” to provide information about the allergy therapy EpiPen (epinephrine) as… Read more »

Corporate, Government, Pharmaceuticals    Adrenaclick, Albuterol, American Medical Association, Ashish Advani, Auvi-Q, CNN, Daraprim, Department of Health and Human Services, Epipen, Ezekiel Emanuel, Federal Trade Commission, FirstWord Pharma, Fortune, Heather Bresch, Johnson & Johnson, Lyrica, Merck KgAA, Mylan NV, Nina Devlin, Pharmacy Times, Sanofi SA, Teva Pharmaceutical Industries Ltd., The New York Times, Turing Pharmaceuticals AG, Washington Post

Search The Site

Follow @MonMorningNews

Twitter

Tweets by MonMorningNews
Follow me on Blogarama

Facebook

Search The Site

More MondayMorning

  • Recent Posts
  • Most Commented
  • Most Viewed
  • Healthcare stocks roar back after slump, while biotech IPOs continue stampede into pipeline.
  • Smartphones are revolutionizing medicine as new apps proliferate. Then there’s the Facebook lesson for and against trusting that your data...
  • US citizen denied life-saving bone-marrow transplant from Iranian brother due to Trump travel ban. My very brief take.
  • Report says hardly any physicians read the medical journals for their particular field. Has era of “evidence-free medicine” finally arrived?
  • Tiny Scottish biotech TauRx lobs bomb into Alzheimer’s fracas with Phase 3 success.
  • CAR-T Therapy: Personalized medicine with the promise of a cure; payers will decide who gets it
  • Akebia shares soar on rich partnership with Otsuka; risky but rational gamble?
  • Although more expensive, study says teaching hospitals save more lives. My personal take.
  • Tiny Scottish biotech TauRx lobs bomb into Alzheimer’s fracas with Phase 3 success.
  • Breakthrough study linking menopause to increased risk of Alzheimer’s explains why far more women than men get the disease; what...
  • Alarming study concludes most new, pricey cancer drugs don’t work; why are we just hearing about this?
  • Rx Hall of Shame Update: Former Insys employee pleads guilty in US opioid drug probe; case against ex CEO Michael...
Copyright 2018
Ribosome by GalussoThemes.com
Powered by WordPress